Stay updated with breaking news from Patent Cliff. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Healthcare M&A deals are expected to pick up over the next few months, and one expert is predicting that the biopharma sector in particular will see especially robust activity. M&A lawyer Matt Gardella said there are three sets of market circumstances that will lead to an influx of biopharma deals: a looming patent cliff, shrinking valuations and a weak IPO market.
A patent cliff, when products go off-patent, is approaching and this could help domestic pharma majors
The brokerage firm sees domestic branded formulations-focused firms' growth rate in the mid-teen range, driven by a high single-digit increase in prices
A patent cliff refers to the end of IP protection for a drug that has enjoyed market exclusivity since its launch. Between now and 2030, the biopharma sector is expected to be rocked by a number of high profile patent cliffs that are likely to reshape the market.
/PRNewswire/ -- Impact BioMedical, in concert with its research partner Global Research and Discovery Group, find themselves in the right place at the right...